Citi analyst Samantha Semenkow lowered the firm’s price target on Editas Medicine to $15 from $16 and keeps a Buy rating on the shares post the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
- Editas Medicine, Bristol Myers extend alpha-beta T cell collaboration
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine management to meet with Oppenheimer
